Kythera's injectable deoxycholic acid-based drug reduced submental fat better than placebo in two Phase III clinical trials, the company announced.
Injection for submental fat meets clinical trial endpoints
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan